Physician profile
John M Williams
NPI 1790880714
$2,033.18
in general payments reported to CMS, 2019-2025
20 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $37.10 · 2021: $134 · 2022: $423 · 2023: $553 · 2024: $313 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.71 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $519.05 | 2022-2025 | Miebo, Xiidra, Infuse Multifocal |
| Alcon Vision LLC | $264.70 | 2019-2024 | Rocklatan |
| Novartis Pharmaceuticals Corporation | $212.85 | 2019-2023 | |
| Horizon Therapeutics Plc | $179.69 | 2022-2023 | Tepezza |
| Abbvie INC. | $142.02 | 2022-2023 | Xen Glaucoma Treatment System |
| Harrow Eye, LLC | $100.72 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $85.61 | 2023-2024 | Cequa |
| Tarsus Pharmaceuticals, INC. | $73.65 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $68.84 | 2019-2025 | Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.68 | 2019-2021 | |
| Shire North American Group INC | $59.65 | 2019 | |
| Coopervision INC. | $56.41 | 2023-2024 | Misight Contact Lens, Myday Contact Lens |
| Aerie Pharmaceuticals, INC. | $41.43 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $32.70 | 2023 | Tecnis Iol |
| Genentech USA, INC. | $29.20 | 2025 | Vabysmo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $28.96 | 2025 | Izervay |
| Allergan, INC. | $27.79 | 2021 | |
| Apellis Pharmaceuticals, INC. | $18.07 | 2023 | |
| Biotissue Holdings INC. | $16.19 | 2023 | |
| Kala Pharmaceuticals, INC. | $14.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.